How do we image patients with multiple myeloma and precursor states?

Abstract

SummaryAdvances in morphological and functional imaging have led to superior detection of early bone disease, bone marrow infiltration, paramedullary and extramedullary involvement in multiple myeloma. The two functional imaging modalities that are most widely used and standardized are 18F‐fluorodeoxyglucose–Positron emission tomography/computed tomography (FDG PET/CT) and whole‐body magnetic resonance imaging with diffusion‐weighted imaging (WB DW‐MRI). Both prospective and retrospective studies have demonstrated that WB DW‐MRI is more sensitive than PET/CT in the detection of baseline tumour burden and to assess response after therapy. In patients with smouldering multiple myeloma, WB DW‐MRI is now the preferred imaging modality to rule out two or more unequivocal lesions which would be considered a myeloma‐defining event by the updated international myeloma working group (IMWG) criteria. In addition to sensitive detection of baseline tumour burden, both PET/CT and WB DW‐MRI have been successfully used for monitoring response to therapy and provide information that is complementary to IMWG response assessment and bone marrow minimal residual disease. In this article, we present 3 vignettes illustrating how we approach the use of modern imaging in the management of patients with multiple myeloma and precursor states, with a specific focus on recent data that have emerged since the publication of the IMWG consensus guideline on imaging. We have utilized data from prospective and retrospective studies to provide a rationale for our approach to imaging in these clinical scenarios and highlighted knowledge gaps requiring future investigation.